Prevalence of Amiodarone-Induced Thyrotoxicosis and Associated Risk Factors in Japanese Patients
Table 1
Clinical features of patients treated with amiodarone with/without the onset of AIT.
AIT (−)
AIT (+)
Patients number
212
13
Gender (Male/Female)
177/35
11/2
0.915
Age (yrs)
<0.001
TSH (U/mL)
0.337
Free T3 (pg/mL)
0.428
Free T4 (ng/dL)
0.484
Observation period (days)
1333 (709.5–2464)
970 (899–1462)
0.362
Cumulative dosage of AMD (g)
137 (52–265)
194 (142–252)
0.256
Cardiac disorders
Chronic heart failure
208
12
0.930
Left ventricular systolic dysfunction
126
6
Ischemic heart disease
96
5
Arrhythmia
NSVT
162
11
0.410
Ventricular fibrillation
18
2
Atrial fibrillation
44
1
Cardiac medications
-blockers
2
0
0.725
-blockers
170
12
0.28
Anti-angiotensin agents
143
10
0.477
Anti-aldosteron agents
84
8
0.119
Diuretics
131
8
0.985
Antithrombotic agents
179
10
0.473
Nitrates
32
2
0.977
Calcium channel blockers
35
2
0.915
Other antiarrhythmic agents
14
0
0.339
NSVT: nonsustained ventricular tachycardia. Data of observation period and cumulative dosage of amiodarone (AMD) are expressed as median (IQR). Other data are expressed as mean ± SD.
